Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IART Integra LifeSciences	$12.59 -4.4%	$12.80	$11.06 ▼ $32.66	$1.02B	1.15	970,843 shs	692,979 shs
ICUI ICU Medical	$132.16 -3.7%	$133.70	$117.92 ▼ $196.26	$3.38B	0.87	259,275 shs	140,620 shs
NUVA NuVasive	$39.75	$39.64	$35.17 ▼ $49.53	$2.08B	1.07	1.16 million shs	N/A
NVRO Nevro	$5.85 +0.1%	$5.85	$3.17 ▼ $10.37	$224.32M	0.81	802,529 shs	753,602 shs
TNDM Tandem Diabetes Care	$15.59 -3.6%	$20.29	$15.17 ▼ $48.24	$1.08B	1.48	1.49 million shs	1.53 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IART Integra LifeSciences	-4.40%	-6.64%	-1.87%	-25.90%	-57.05%
ICUI ICU Medical	-3.72%	-2.46%	-1.70%	-7.35%	+7.45%
NUVA NuVasive	0.00%	0.00%	0.00%	0.00%	0.00%
NVRO Nevro	0.00%	0.00%	0.00%	0.00%	-27.02%
TNDM Tandem Diabetes Care	-3.59%	-8.64%	-27.66%	-8.62%	-64.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IART Integra LifeSciences	4.1548 of 5 stars	2.9	1.0	0.0	4.0	2.1	1.7	2.5
ICUI ICU Medical	4.4144 of 5 stars	3.5	1.0	0.0	3.9	2.6	2.5	1.9
NUVA NuVasive	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NVRO Nevro	0.1623 of 5 stars	1.0	0.0	0.0	0.0	0.0	1.7	0.6
TNDM Tandem Diabetes Care	4.1295 of 5 stars	4.2	1.0	0.0	4.9	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IART Integra LifeSciences	1.78	Reduce	$18.63	47.93% Upside
ICUI ICU Medical	3.00	Buy	$192.67	45.78% Upside
NUVA NuVasive	0.00	N/A	N/A	N/A
NVRO Nevro	1.92	Reduce	$5.36	-8.29% Downside
TNDM Tandem Diabetes Care	2.33	Hold	$32.71	109.84% Upside

Current Analyst Ratings Breakdown

Latest NUVA, TNDM, ICUI, NVRO, and IART Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	TNDM Tandem Diabetes Care	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell	$24.00 ➝ $14.00
6/16/2025	TNDM Tandem Diabetes Care	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$24.00
5/22/2025	TNDM Tandem Diabetes Care	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $24.00
5/9/2025	IART Integra LifeSciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$35.00 ➝ $25.00
5/9/2025	ICUI ICU Medical	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$197.00 ➝ $187.00
5/6/2025	IART Integra LifeSciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $13.00
5/6/2025	IART Integra LifeSciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$24.00 ➝ $12.00
5/1/2025	TNDM Tandem Diabetes Care	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $59.00
5/1/2025	TNDM Tandem Diabetes Care	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $31.00
5/1/2025	TNDM Tandem Diabetes Care	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$22.00 ➝ $20.00
5/1/2025	TNDM Tandem Diabetes Care	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$36.00 ➝ $30.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IART Integra LifeSciences	$1.61B	0.61	$4.25 per share	2.96	$20.03 per share	0.63
ICUI ICU Medical	$2.38B	1.37	$13.50 per share	9.79	$80.26 per share	1.65
NUVA NuVasive	$1.23B	1.70	$4.96 per share	8.01	$17.02 per share	2.34
NVRO Nevro	$408.52M	0.55	N/A	N/A	$8.10 per share	0.72
TNDM Tandem Diabetes Care	$940.20M	1.10	N/A	N/A	$4.01 per share	3.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IART Integra LifeSciences	-$6.94M	-$0.38	N/A	5.04	0.73	-1.78%	12.12%	4.58%	8/4/2025 (Estimated)
ICUI ICU Medical	-$117.69M	-$3.83	N/A	24.29	N/A	-3.87%	6.75%	3.20%	8/6/2025 (Estimated)
NUVA NuVasive	$40.41M	$0.50	79.50	15.35	N/A	2.32%	12.17%	4.88%	N/A
NVRO Nevro	-$92.21M	-$3.05	N/A	N/A	N/A	-16.54%	-23.52%	-10.83%	8/4/2025 (Estimated)
TNDM Tandem Diabetes Care	-$96.03M	-$2.78	N/A	N/A	N/A	-18.71%	-57.33%	-13.48%	8/6/2025 (Confirmed)

Latest NUVA, TNDM, ICUI, NVRO, and IART Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ICUI ICU Medical	$1.44	N/A	N/A	N/A	$543.33 million	N/A
8/6/2025	Q2 2025	TNDM Tandem Diabetes Care	-$0.40	N/A	N/A	N/A	$238.39 million	N/A
8/4/2025	Q2 2025	IART Integra LifeSciences	$0.43	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	ICUI ICU Medical	$1.23	$1.72	+$0.49	-$0.63	$574.15 million	$599.49 million
5/5/2025	Q1 2025	IART Integra LifeSciences	$0.43	$0.41	-$0.02	-$0.33	$381.17 million	$382.65 million
4/30/2025	Q1 2025	TNDM Tandem Diabetes Care	-$0.60	-$0.67	-$0.07	-$1.97	$220.19 million	$234.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IART Integra LifeSciences	N/A	N/A	N/A	N/A	N/A
ICUI ICU Medical	N/A	N/A	N/A	N/A	N/A
NUVA NuVasive	N/A	N/A	N/A	N/A	N/A
NVRO Nevro	N/A	N/A	N/A	N/A	N/A
TNDM Tandem Diabetes Care	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IART Integra LifeSciences	0.81	1.21	0.72
ICUI ICU Medical	0.75	2.59	1.52
NUVA NuVasive	0.50	1.25	0.65
NVRO Nevro	0.67	5.02	3.76
TNDM Tandem Diabetes Care	1.99	2.30	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IART Integra LifeSciences	84.78%
ICUI ICU Medical	96.10%
NUVA NuVasive	N/A
NVRO Nevro	95.52%
TNDM Tandem Diabetes Care	N/A

Insider Ownership

Company	Insider Ownership
IART Integra LifeSciences	3.54%
ICUI ICU Medical	1.50%
NUVA NuVasive	0.53%
NVRO Nevro	3.20%
TNDM Tandem Diabetes Care	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IART Integra LifeSciences	4,396	77.71 million	74.96 million	Optionable
ICUI ICU Medical	15,000	24.61 million	24.24 million	Optionable
NUVA NuVasive	3,000	52.45 million	52.17 million	Optionable
NVRO Nevro	1,090	38.37 million	36.27 million	Optionable
TNDM Tandem Diabetes Care	2,650	66.61 million	65.34 million	Optionable

NUVA, TNDM, ICUI, NVRO, and IART Headlines

Recent News About These Companies

Earnings Forecast & History for Tandem Diabetes Care Inc (TNDM) | Price ...

July 12 at 6:25 AM | investing.com

Citigroup Reaffirms Sell Rating for Tandem Diabetes Care (NASDAQ:TNDM)

July 11 at 2:21 AM | americanbankingnews.com

Tandem Diabetes stock falls after Citi downgrades to Sell on competition concerns

July 9 at 6:56 PM | au.investing.com

Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes

July 9 at 6:56 PM | finance.yahoo.com

Tandem Diabetes Shares Drop Following Citi Downgrade Over Rising Competition

July 9 at 6:56 PM | msn.com

Why Tandem Diabetes (TNDM) Shares Are Sliding Today

July 9 at 6:56 PM | msn.com

Tandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month Low - Here's Why

July 9 at 12:15 PM | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Given "Sell" Rating at Citigroup

July 9 at 8:40 AM | marketbeat.com

Further weakness as Tandem Diabetes Care (NASDAQ:TNDM) drops 10.0% this week, taking five-year losses to 83%

July 7, 2025 | finance.yahoo.com

Mirae Asset Global Investments Co. Ltd. Sells 265,554 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

July 6, 2025 | marketbeat.com

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 - Morningstar

July 2, 2025 | morningstar.comM

RSI Alert: Tandem Diabetes Care (TNDM) Now Oversold

July 2, 2025 | nasdaq.com

TNDM - Tandem Diabetes Care Inc Key Metrics - Morningstar

July 1, 2025 | morningstar.comM

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

July 1, 2025 | businesswire.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down - Here's Why

July 1, 2025 | marketbeat.com

TNDM - Tandem Diabetes Care Inc Financials - Morningstar

June 27, 2025 | morningstar.comM

The 5 Most Interesting Analyst Questions From Tandem Diabetes’s Q1 Earnings Call

June 27, 2025 | msn.com

TNDM | Tandem Diabetes Care Inc. Annual Cash Flow Statement - MarketWatch

June 26, 2025 | marketwatch.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Down 5.9% - Time to Sell?

June 25, 2025 | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Recommendation of "Hold" by Brokerages

June 25, 2025 | marketbeat.com

Tandem Diabetes Care Inc TNDM Company Vitals - U.S. News

June 24, 2025 | money.usnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICUI, NUVA, TNDM, NVRO, and IART Company Descriptions

Integra LifeSciences NASDAQ:IART

$12.59 -0.58 (-4.40%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$12.57 -0.02 (-0.16%)

As of 07/11/2025 07:30 PM Eastern

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

ICU Medical NASDAQ:ICUI

$132.16 -5.10 (-3.72%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$132.22 +0.06 (+0.04%)

As of 07/11/2025 05:23 PM Eastern

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

NuVasive NASDAQ:NUVA

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.

Nevro NYSE:NVRO

$5.85 +0.01 (+0.10%)

Closing price 04/2/2025

Extended Trading

$5.85 0.00 (0.00%)

As of 04/2/2025 07:56 PM Eastern

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Tandem Diabetes Care NASDAQ:TNDM

$15.59 -0.58 (-3.59%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$15.74 +0.15 (+0.96%)

As of 07/11/2025 07:35 PM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time